

# Benoit Rousseau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3158802/publications.pdf>

Version: 2024-02-01

83  
papers

3,255  
citations

236925

25  
h-index

175258

52  
g-index

95  
all docs

95  
docs citations

95  
times ranked

4864  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
2	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. <i>Hepatology</i> , 2016, 64, 2038-2046.	7.3	343
3	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	3.7	219
4	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
5	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 24644-24651.	1.8	146
6	Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2013, 34, 570-577.	2.2	145
7	The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. <i>New England Journal of Medicine</i> , 2021, 384, 1168-1170.	27.0	137
8	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	28.9	131
9	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129
10	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 2046-2049.	2.6	95
11	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363.	0.9	80
12	Alternative <i>Neisseria</i> spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14783-14788.	7.1	77
13	<i>KRAS</i> oncogene in lung cancer: focus on molecularly driven clinical trials. <i>European Respiratory Review</i> , 2016, 25, 71-76.	7.1	72
14	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 242-248.	4.4	68
15	Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. <i>Annals of Oncology</i> , 2012, 23, 450-457.	1.2	67
16	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	3.6	65
17	Immune Therapy for Liver Cancers. <i>Cancers</i> , 2020, 12, 77.	3.7	49
18	FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. <i>World Journal of Gastroenterology</i> , 2012, 18, 4533.	3.3	41

#	ARTICLE	IF	CITATIONS
19	Stage II and Stage III Colon Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2010, 16, 202-209.	2.0	39
20	CD4 T Cellâ€“Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repairâ€“Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	9.4	37
21	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
22	Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	35
23	Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LCâ€“MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 42-48.	2.8	34
24	BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. <i>British Journal of Surgery</i> , 2019, 106, 1237-1247.	0.3	33
25	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	2.8	32
26	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. <i>Oncotarget</i> , 2017, 8, 101383-101393.	1.8	31
27	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
28	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 44-53.	4.4	25
29	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
30	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22
31	Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PATients) cohort. <i>Journal of Geriatric Oncology</i> , 2020, 11, 586-592.	1.0	22
32	Characteristics of <i>BRAF</i> <i>V600E</i> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	3.7	20
33	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. <i>British Journal of Cancer</i> , 2015, 113, 1313-1322.	6.4	19
34	Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. <i>Clinical and Translational Radiation Oncology</i> , 2018, 10, 13-22.	1.7	18
35	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	5.1	17
36	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	2.8	15

#	ARTICLE	IF	CITATIONS
37	<i>NF1</i> mutations identify molecular and clinical subtypes of lung adenocarcinomas. Cancer Medicine, 2019, 8, 4330-4337.	2.8	14
38	Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis. Breast Cancer Research and Treatment, 2016, 157, 191-192.	2.5	12
39	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clinical Genitourinary Cancer, 2020, 18, 295-303.e3.	1.9	12
40	Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer. JAMA Oncology, 2021, 7, 1686.	7.1	11
41	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
42	RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. Cancer Imaging, 2019, 19, 85.	2.8	9
43	Evaluation of<i> POLE/POLD1</i> Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. JAMA Oncology, 2020, 6, 589.	7.1	8
44	Is there a withdrawal syndrome with abiraterone acetate (AA)?. Journal of Clinical Oncology, 2013, 31, 89-89.	1.6	8
45	Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma. Investigational New Drugs, 2019, 37, 1289-1291.	2.6	7
46	Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?. Journal of Clinical Oncology, 2015, 33, 2484-2485.	1.6	6
47	What Do Older Adults Know About Their Cancer Diagnosis and Treatment? The ELCAPAâ€ Cohort Study. Journal of the American Geriatrics Society, 2016, 64, 1360-1362.	2.6	6
48	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. European Journal of Cancer, 2016, 66, 75-82.	2.8	5
49	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. Clinical Colorectal Cancer, 2021, 20, 79-83.e4.	2.3	4
50	Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion. Medicine (United States), 2016, 95, e4006.	1.0	3
51	Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy. Clinical Genitourinary Cancer, 2016, 14, e95-e97.	1.9	3
52	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	2.6	3
53	Withholding the Introduction of Antiâ€ Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wildâ€ Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). Oncologist, 2020, 25, e266-e275.	3.7	3
54	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. European Journal of Cancer, 2022, 168, 99-107.	2.8	3

#	ARTICLE	IF	CITATIONS
55	Mécanismes de résistances aux inhibiteurs de RAF : revue de la littérature. <i>Oncologie</i> , 2012, 14, 2-4.	0.7	2
56	Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey. <i>Annals of Oncology</i> , 2019, 30, v210.	1.2	2
57	FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 272-272.	1.6	2
58	Potential drug interactions in older patients with cancer: Updated data from the ELCAPA cohort survey. <i>Annals of Oncology</i> , 2017, 28, v557-v558.	1.2	1
59	Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: Results of a single-institution phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 37-37.	1.6	1
60	Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 354-354.	1.6	1
61	Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3121-3121.	1.6	1
62	Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma. <i>Oncotarget</i> , 2019, 10, 2789-2790.	1.8	1
63	Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4106-4106.	1.6	1
64	REVIEW OF 433 PATIENTS HIGHLY OVEREXPOSED DURING RADIOTHERAPY FOR PROSTATE CANCER. <i>Radiotherapy and Oncology</i> , 2011, 98, S42-S43.	0.6	0
65	1549 Blood alcohol level in patients treated with gemcitabine and taxanes. <i>European Journal of Cancer</i> , 2015, 51, S220-S221.	2.8	0
66	Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient mismatch repair (pMMR) colorectal and endometrial cancers. <i>Annals of Oncology</i> , 2018, 29, viii34.	1.2	0
67	Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR) $T_j ETQq1110,784314,0gBT / O$	1.2	0
68	Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort. <i>Annals of Oncology</i> , 2018, 29, viii186.	1.2	0
69	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations. <i>Annals of Oncology</i> , 2018, 29, viii261-viii262.	1.2	0
70	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	0
71	Sorafenib discontinuation due to toxicity: A literature-based meta-analysis and meta-regression analysis of 18 randomized controlled trials in solid and hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13545-e13545.	1.6	0
72	Abstract P5-15-12: Clinico-biological characteristics of patients surviving more than two years with metastatic breast cancer (MBC): Results of a transversal national multicentric survey. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
73	Relationship between response and progression free survival in 8965 patients with advanced renal cell carcinoma treated with first-line antiangiogenic therapy in 39 trials.. Journal of Clinical Oncology, 2015, 33, e15581-e15581.	1.6	0
74	Blood alcohol level in patients treated with gemcitabine and taxanes.. Journal of Clinical Oncology, 2015, 33, e17664-e17664.	1.6	0
75	First line antiangiogenics for advanced renal cell carcinoma: A systematic review and network meta-analysis comparing efficacy and toxicities.. Journal of Clinical Oncology, 2015, 33, e15586-e15586.	1.6	0
76	Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.. Journal of Clinical Oncology, 2016, 34, 4076-4076.	1.6	0
77	Multimodal treatment choice and feasibility in older patients with resectable gastric cancer: a multicentric cohort study.. Journal of Clinical Oncology, 2016, 34, e15528-e15528.	1.6	0
78	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.. Journal of Clinical Oncology, 2018, 36, e16119-e16119.	1.6	0
79	Abstract 5511: Characterization of molecular and functional consequences of somaticNF1 mutations in non-small cell lung cancers. , 2018, , .		0
80	Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	0
81	Abstract 91: Diet-variants and immune characterization of a stage-defined, transgenic immunocompetent mouse model of HCC (ASV-B). , 2019, , .		0
82	Clinical criteria predicting an overall survival benefit to platinum rechallenge (PR) in metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2020, 38, 490-490.	1.6	0
83	High prevalence of unusual <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in <i>POLE</i> hypermutated colorectal cancers. Molecular Oncology, 2022, 16, 3055-3065.	4.6	0